(Q51478110)

English

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

scientific article published in March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. (English)

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

M A Nauck

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

G Meininger

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

D Sheng

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

L Terranella

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

P P Stein

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

Sitagliptin Study 024 Group

6

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

publication date

1 March 2007

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

9

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

194-205

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Metformin: new understandings, new uses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Fat in the liver and insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2006.00704.X

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300595

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51478110&oldid=1743643627"